CCR7 Mediated Mimetic Dendritic Cell Vaccine Homing in Lymph Node for Head and Neck Squamous Cell Carcinoma Therapy

Authors

Jiabin Xu
Hong Liu
Tao Wang
Zhenfu Wen
Haolin Chen
Zeyu Yang
Liyan Li
Shan Yu
Siyong Gao
Le Yang
Kan Li
Jingyuan Li
Xiang Li
Lixin Liu
Guiqing Liao
Yongming Chen
Yujie Liang

Publication Date

6-1-2023

Journal

Advanced Science

Abstract

Immunotherapy has been recognized as one of the most promising treatment strategies for head and neck squamous cell carcinoma (HNSCC). As a pioneering trend of immunotherapy, dendritic cell (DC) vaccines have displayed the ability to prime an immune response, while the insufficient immunogenicity and low lymph node (LN) targeting efficiency, resulted in an unsubstantiated therapeutic efficacy in clinical trials. Herein, a hybrid nanovaccine (Hy-M-Exo) is developed via fusing tumor-derived exosome (TEX) and dendritic cell membrane vesicle (DCMV). The hybrid nanovaccine inherited the key protein for lymphatic homing, CCR7, from DCMV and demonstrated an enhanced efficiency of LN targeting. Meanwhile, the reserved tumor antigens and endogenous danger signals in the hybrid nanovaccine activated antigen presenting cells (APCs) elicited a robust T-cell response. Moreover, the nanovaccine Hy-M-Exo displayed good therapeutic efficacy in a mouse model of HNSCC. These results indicated that Hy-M-Exo is of high clinical value to serve as a feasible strategy for antitumor immunotherapy.

Keywords

Mice, Animals, Squamous Cell Carcinoma of Head and Neck, Receptors, CCR7, Head and Neck Neoplasms, Dendritic Cells, Lymph Nodes, Vaccines

Comments

Supplementary Materials

PMID: 37092579